Proteomics analysis of Hodgkin lymphoma: identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes.

Hodgkin and Reed-Sternberg (HRS) cells in Hodgkin lymphoma (HL) secrete factors that interact with inflammatory background cells and may serve as biomarkers for disease activity. To detect new proteins related to pathogenesis, we analyzed the secretome of HRS cells. Proteins in cell culture supernatant of 4 HL cell lines were identified using 1DGE followed by in-gel trypsin digestion and LC-MS/MS. In total, 1290 proteins, including 368 secreted proteins, were identified. Functional grouping of secreted proteins revealed 37 proteins involved in immune response. Sixteen of the 37 proteins (ie, ALCAM, Cathepsin C, Cathepsin S, CD100, CD150, CD26, CD44, CD63, CD71, Fractal-kine, IL1R2, IL25, IP-10, MIF, RANTES, and TARC) were validated in HL cell lines and patient material using immunohistochemistry and/or ELISA. Expression of all 16 proteins was confirmed in HL cell lines, and 15 were also confirmed in HL tissues. Seven proteins (ALCAM, cathepsin S, CD26, CD44, IL1R2, MIF, and TARC) revealed significantly elevated levels in patient plasma compared with healthy controls. Proteomics analyses of HL cell line supernatant allowed detection of new secreted proteins, which may add to our insights in the interaction between HRS cells and infiltrating lymphocytes and in some instances might serve as biomarkers.

[1]  A. Mantovani,et al.  The type II 'decoy' receptor: a novel regulatory pathway for interleukin 1. , 1994, Immunology today.

[2]  F. Herrmann,et al.  Hodgkin's disease: a tumor with disturbed immunological pathways. , 1997, Immunology today.

[3]  S. P. Sidorenko,et al.  Characterization of a cell surface glycoprotein IPO-3, expressed on activated human B and T lymphocytes. , 1993, Journal of immunology.

[4]  Sean L Seymour,et al.  Discovering known and unanticipated protein modifications using MS/MS database searching. , 2005, Analytical chemistry.

[5]  B. Cocks,et al.  Soluble and Membrane-bound Forms of Signaling Lymphocytic Activation Molecule (SLAM) Induce Proliferation and Ig Synthesis by Activated Human B Lymphocytes , 1997, The Journal of experimental medicine.

[6]  N. Blom,et al.  Feature-based prediction of non-classical and leaderless protein secretion. , 2004, Protein engineering, design & selection : PEDS.

[7]  C. Herling,et al.  Immunopathology and Infectious Disease Circulating CD26 Is Negatively Associated with Inflammation in Human and Experimental Arthritis , 2022 .

[8]  B. Wolffenbuttel,et al.  Characterization of the Human Visceral Adipose Tissue Secretome*S , 2007, Molecular & Cellular Proteomics.

[9]  Nelson Spector,et al.  Differential protein expression patterns obtained by mass spectrometry can aid in the diagnosis of Hodgkin's disease. , 2007, Journal of experimental therapeutics & oncology.

[10]  E. Kashuba,et al.  The role of CD150-SH2D1A association in CD150 signaling in Hodgkin's lymphoma cell lines. , 2005, Experimental oncology.

[11]  A. Diepstra,et al.  Common and differential chemokine expression patterns in rs cells of NLP, EBV positive and negative classical hodgkin lymphomas , 2002, International journal of cancer.

[12]  M. Samoszuk,et al.  Detection of interleukin-5 messenger RNA in Reed-Sternberg cells of Hodgkin's disease with eosinophilia. , 1990, Blood.

[13]  J. Crocker,et al.  Immunohistochemical demonstration of cathepsin B in the macrophages of benign and malignant lymphoid tissues , 1984, The Journal of pathology.

[14]  R. Gascoyne,et al.  Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. , 2001, Blood.

[15]  S. Uccini,et al.  Cytokine Production (IL-1α, IL-1β, and TNFα) and Endothelial Cell Activation (ELAM-1 and HLA-DR) in Reactive Lymphadenitis, Hodgkin's Disease, and in Non-Hodgkin's Lymphomas: An Immunocytochemical Study , 1990 .

[16]  S. Hirohashi,et al.  Protein expression pattern distinguishes different lymphoid neoplasms , 2005, Proteomics.

[17]  M. Gayle,et al.  Interleukin 1 signaling occurs exclusively via the type I receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[18]  L. Pannell,et al.  Secretory protein enrichment and analysis: an optimized approach applied on cancer cell lines using 2D LC-MS/MS. , 2006, Journal of proteome research.

[19]  L. Leng,et al.  CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. , 2006, Immunity.

[20]  R. Kalluri,et al.  Cathepsin S Controls Angiogenesis and Tumor Growth via Matrix-derived Angiogenic Factors* , 2006, Journal of Biological Chemistry.

[21]  L. Mazzucchelli,et al.  CC chemokines and the receptors CCR3 and CCR5 are differentially expressed in the nonneoplastic leukocytic infiltrates of Hodgkin disease. , 2001, Blood.

[22]  S. Poppema.  Immunobiology and pathophysiology of Hodgkin lymphomas. , 2005, Hematology. American Society of Hematology. Education Program.

[23]  M. Chilosi,et al.  Two‐dimensional molecular profiling of mantle cell lymphoma , 2003, Electrophoresis.

[24]  K. Ishizawa,et al.  CD26, together with cell surface adenosine deaminase, is selectively expressed on ALK-positive, but not on ALK-negative, anaplastic large cell lymphoma and Hodgkin's lymphoma , 2006, Leukemia & lymphoma.

[25]  K. Zatloukal,et al.  Expression of CD44 splice variant v10 in Hodgkin's disease is associated with aggressive behaviour and high risk of relapse , 1998, The Journal of pathology.

[26]  T. Mcclanahan,et al.  Interleukin 25 regulates type 2 cytokine-dependent immunity and limits chronic inflammation in the gastrointestinal tract , 2006, The Journal of experimental medicine.

[27]  H. Drexler.  Recent results on the biology of Hodgkin and Reed-Sternberg cells. I. Biopsy material. , 1992, Leukemia & lymphoma.

[28]  G. Nilsson,et al.  Expression of CCL5/RANTES by Hodgkin and Reed‐Sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue , 2003, International journal of cancer.

[29]  Douglas A. Hosack,et al.  Identifying biological themes within lists of genes with EASE , 2003, Genome Biology.

[30]  L. Leng,et al.  MIF Signal Transduction Initiated by Binding to CD74 , 2003, The Journal of experimental medicine.

[31]  T. Mak,et al.  The role of cytokines in classical Hodgkin lymphoma. , 2002, Blood.

[32]  P. Libby,et al.  Deficiency of the Cysteine Protease Cathepsin S Impairs Microvessel Growth , 2003, Circulation research.

[33]  Q. Hamid,et al.  IL-17E upregulates the expression of proinflammatory cytokines in lung fibroblasts. , 2006, The Journal of allergy and clinical immunology.

[34]  M. Leach,et al.  IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. , 2001, Immunity.

[35]  K. Ohshima,et al.  Infiltration of Th1 and Th2 lymphocytes around Hodgkin and Reed‐Sternberg (H&RS) cells in Hodgkin disease: Relation with expression of CXC and CC chemokines on H&RS cells , 2002, International journal of cancer.

[36]  M. Parmentier,et al.  Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. , 2001, Blood.

[37]  J. J. van den Oord,et al.  Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin. , 2000, The American journal of pathology.

[38]  J. Delabie,et al.  The expression of fibroblast growth factors and their receptors in Hodgkin's lymphoma , 2006, The Journal of pathology.

[39]  P. Proost,et al.  The role of CD26/DPP IV in chemokine processing. , 1999, Chemical immunology.

[40]  F. Malavasi,et al.  CD57 Workshop Panel Report , 1997 .

[41]  S. Levy,et al.  The tetraspanin superfamily: molecular facilitators , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[42]  R. Bucala,et al.  Regulation of the CTL Response by Macrophage Migration Inhibitory Factor , 2001, The Journal of Immunology.

[43]  A. Sherrod,et al.  Immunohistologic identification of phenotypic antigens associated with Hodgkin and reed‐sternberg cells. A paraffin section study , 1986, Cancer.

[44]  B. Haynes,et al.  Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand , 1995, The Journal of experimental medicine.

[45]  Maria Jesus Martin,et al.  The SWISS-PROT protein knowledgebase and its supplement TrEMBL in 2003 , 2003, Nucleic Acids Res..

[46]  S. Hanash.  Disease proteomics : Proteomics , 2003 .

[47]  B. Dörken,et al.  High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. , 1996, Blood.

[48]  N. Siafakas,et al.  Angiogenic molecules in Hodgkin's disease: results from sequential serum analysis. , 2006, International journal of immunopathology and pharmacology.

[49]  V. Diehl,et al.  Profiling of Hodgkin’s Lymphoma Cell Line L1236 and Germinal Center B Cells: Identification of Hodgkin’s Lymphoma-specific Genes , 2003 .

[50]  K. Kok,et al.  Global correlation of genome and transcriptome changes in classical Hodgkin lymphoma , 2007, Hematological oncology.

[51]  V. Diehl,et al.  Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor. , 2005, Cancer research.

[52]  R. Coffman,et al.  New IL-17 Family Members Promote Th1 or Th2 Responses in the Lung: In Vivo Function of the Novel Cytokine IL-251 , 2002, The Journal of Immunology.

[53]  B. Fleischer,et al.  CD26: a surface protease involved in T-cell activation. , 1994, Immunology today.

[54]  S. Uccini,et al.  Cytokine production (IL-1 alpha, IL-1 beta, and TNF alpha) and endothelial cell activation (ELAM-1 and HLA-DR) in reactive lymphadenitis, Hodgkin's disease, and in non-Hodgkin's lymphomas. An immunocytochemical study. , 1990, The American journal of pathology.

[55]  C. Figdor,et al.  Long-term engagement of CD6 and ALCAM is essential for T-cell proliferation induced by dendritic cells. , 2006, Blood.

[56]  S. Iida,et al.  Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. , 2006, Cancer research.

[57]  E. Jaffe,et al.  Differential chemokine expression in tissues involved by Hodgkin's disease: direct correlation of eotaxin expression and tissue eosinophilia. , 1999, Blood.

[58]  S. Hirohashi,et al.  Toward a comprehensive quantitative proteome database: protein expression map of lymphoid neoplasms by 2‐D DIGE and MS , 2006, Proteomics.

[59]  J. Bernhagen,et al.  Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity. , 2006, Cellular signalling.

[60]  S. Hanash,et al.  Disease proteomics , 2003, Nature.

[61]  J. Joyce,et al.  Cysteine Cathepsins and the Cutting Edge of Cancer Invasion , 2007, Cell cycle.

[62]  Nils Blüthgen,et al.  Biological profiling of gene groups utilizing Gene Ontology. , 2004, Genome informatics. International Conference on Genome Informatics.

[63]  B. Cocks,et al.  A novel receptor involved in T-cell activation , 1995, Nature.

[64]  Dominique Schols,et al.  Amino-terminal Truncation of Chemokines by CD26/Dipeptidyl-peptidase IV , 1998, The Journal of Biological Chemistry.

[65]  J. Blay,et al.  Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  J. Imanishi,et al.  Characterization of new human pancreatic cancer cell lines which propagate in a protein-free chemically defined medium. , 1990, Cancer research.

[67]  J. Welsh,et al.  Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[68]  K. Elenitoba-Johnson,et al.  Mass Spectrometry-based Proteomic Studies of Human Anaplastic Large Cell Lymphoma* , 2006, Molecular & Cellular Proteomics.

[69]  B. Wood,et al.  CD44H and CD44V6 Expression in Different Subtypes of Hodgkin Lymphoma , 2000, Modern Pathology.

[70]  A. van den Berg,et al.  High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma. , 1999, The American journal of pathology.